ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Montelukast: Drug information

Montelukast: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Montelukast: Patient drug information" and "Montelukast: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Serious neuropsychiatric events:

Serious neuropsychiatric (NP) events have been reported with the use of montelukast. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with montelukast use are currently not well understood.

Because of the risk of NP events, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of montelukast for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing montelukast.

Discuss the benefits and risks of montelukast with patients and caregivers when prescribing montelukast. Advise patients and/or caregivers to be alert for changes in behavior or new NP symptoms when taking montelukast. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue montelukast and contact a health care provider immediately.

Brand Names: US
  • Singulair
Brand Names: Canada
  • ACH-Montelukast;
  • AG-Montelukast;
  • APO-Montelukast;
  • Auro-Montelukast;
  • BIO-Montelukast;
  • DOM-Montelukast FC [DSC];
  • JAMP-Montelukast;
  • M-Montelukast;
  • Mar-Montelukast;
  • MINT-Montelukast;
  • NAT-Montelukast;
  • NRA-Montelukast;
  • PMS-Montelukast;
  • PRIVA-Montelukast [DSC];
  • RIVA-Montelukast FC;
  • SANDOZ Montelukast;
  • Singulair;
  • TARO-Montelukast;
  • TEVA-Montelukast
Pharmacologic Category
  • Leukotriene Receptor Antagonist
Dosing: Adult
Allergic rhinitis, perennial or seasonal

Allergic rhinitis, perennial or seasonal (alternative agent):

Note: For use only in patients who have an inadequate response to or cannot tolerate other therapy options (Ref). Some experts reserve use to those with coexisting asthma and intolerance to preferred therapies (Ref). Potential benefits of therapy may be outweighed by risk of adverse mood effects (Ref).

Oral: 10 mg once daily.

Aspirin-exacerbated respiratory disease, including aspirin challenge/desensitization

Aspirin-exacerbated respiratory disease, including aspirin challenge/desensitization (adjunct) (off-label use):

Chronic management: Note: May be used as an adjunct to other first-line therapies regardless of symptom control or severity of asthma (Ref).

Oral: 10 mg once daily in the evening (Ref).

Aspirin challenge/desensitization procedures:

Oral: 10 mg once daily starting 3 days before challenge/desensitization or 10 mg twice daily the day before challenge/desensitization followed by 10 mg once daily on each day of the challenge/desensitization (Ref).

Introduction of aspirin before cardiovascular interventions for myocardial infarction:

Note: If the cardiovascular intervention cannot be delayed for ≥3 to 5 hours or in patients with severe aspirin hypersensitivity, some experts use alternative antiplatelet agents instead of aspirin (Ref). Refer to local protocols; if used, administer as part of an appropriate premedication regimen. An example regimen is as follows:

Oral: 10 mg once ≥1 hour prior to the first aspirin dose (Ref).

Asthma, maintenance therapy

Asthma, maintenance therapy (alternative agent):

Note: In patients with mild asthma, may be used as an alternative controller therapy in those who cannot take an inhaled corticosteroid (ICS). In patients with moderate to severe asthma, may be used as an adjunctive controller therapy in those with inadequate symptom control on an ICS (Ref).

Oral: 10 mg once daily in the evening. Some experts suggest waiting 1 to 2 months before assessing efficacy (Ref).

Bronchoconstriction, exercise-induced

Bronchoconstriction, exercise-induced (prevention):

Note: May be used as an adjunctive agent or alternative monotherapy in patients with persistent symptoms on or who cannot take a short-acting beta agonist or in patients who exercise frequently (eg, >3 hours/day or more than once per day) (Ref). In patients receiving daily montelukast for another indication, additional montelukast should not be administered for exercise-induced bronchoconstriction.

Oral: 10 mg ≥2 hours prior to exercise; limit to 1 dose every 24 hours.

Hypersensitivity reactions, rapid chemotherapy/biologics desensitization

Hypersensitivity reactions, rapid chemotherapy/biologics desensitization (premedication) (off-label use):

Note: May be administered as part of an appropriate premedication regimen prior to the infusion of certain chemotherapy agents (eg, platinum-based agents) or biologics in patients who experienced respiratory symptoms during the initial reaction. Administer under close observation and ensure availability of trained clinicians during the procedure. An optimal premedication regimen has not been identified; refer to institutional protocols (Ref).

Oral: 10 mg once daily for 1 to 2 days before the desensitization procedure, then 10 mg 1 hour before the start of the procedure (Ref).

Infusion-related reactions, daratumumab-based regimens

Infusion-related reactions, daratumumab-based regimens (premedication) (off-label use):

Oral: 10 mg administered 30 to 60 minutes prior to the first infusion; for split-dose infusion, administer 10 mg before start of daratumumab on day 1 and day 2; administer as part of an appropriate premedication regimen (Ref).

Urticaria, chronic and delayed pressure

Urticaria, chronic and delayed pressure (adjunct) (off-label use):

Note: May be used as an adjunctive therapy in patients with persistent symptoms despite appropriately titrated antihistamine therapy (Ref).

Oral: 10 mg once daily (Ref). Some experts suggest waiting ≥4 weeks before assessing efficacy (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

Mild to moderate impairment: No dosage adjustment necessary.

Severe impairment: There are no dosage adjustments provided in manufacturer’s labeling; has not been studied.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Montelukast: Pediatric drug information")

Dosage guidance:

Safety: Due to risk of neuropsychiatric adverse effects, the benefits and risks of montelukast should be assessed prior to therapy initiation. Patients with both asthma and allergic rhinitis should take only 1 dose in the evening.

Allergic rhinitis

Allergic rhinitis:

Perennial:

Infants ≥6 months and Children <6 years: Oral: 4 mg once daily.

Children ≥6 years and Adolescents <15 years: Oral: 5 mg once daily.

Adolescents ≥15 years: Oral: 10 mg once daily.

Seasonal:

Children 2 to 5 years: Oral: 4 mg once daily.

Children ≥6 years and Adolescents <15 years: Oral: 5 mg once daily.

Adolescents ≥15 years: Oral: 10 mg once daily.

Asthma, maintenance therapy

Asthma, maintenance therapy: Note: Not preferred therapy for any level of asthma severity; may be considered an alternative option for Step 2 or greater management; inhaled corticosteroids are preferred (Ref).

12 months to 5 years: Oral: 4 mg once daily in the evening.

6 to 14 years: Oral: 5 mg once daily in the evening.

≥15 years: Oral: 10 mg once daily in the evening.

Exercise-induced bronchospasm, prevention

Exercise-induced bronchospasm, prevention:

Note: Additional doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchospasm has not been evaluated. Patients receiving montelukast for another indication should not take an additional dose to prevent exercise-induced bronchoconstriction.

Children ≥6 years and Adolescents <15 years: Oral: 5 mg at least 2 hours prior to exercise.

Adolescents ≥15 years: Tablet: Oral: 10 mg at least 2 hours prior to exercise.

Urticaria

Urticaria (nonsteroidal anti-inflammatory drug-induced): Limited data available: Adolescents ≥15 years: Oral: 10 mg once daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

No adjustment necessary.

Dosing: Hepatic Impairment: Pediatric

Mild to moderate impairment: No dosage adjustment necessary.

Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.

Adverse Reactions (Significant): Considerations
Neuropsychiatric reactions

Various neuropsychiatric adverse reactions, which may lead to drug discontinuation, have been reported with montelukast in patients with and without a history of psychiatric illness (Benard 2017; FDA 2020). Reactions have been reported in adult and pediatric patients; however, reactions are more commonly reported in pediatric patients, possibly due to the increased use of the drug in this population (Perona 2016). Reactions include nervous system disorders (eg, disturbance in attention, memory impairment, stuttering, tic disorder, seizure), psychiatric disturbances (eg, agitation, aggressive behavior, anxiety, depression, disorientation, hallucination, irritability, obsessive compulsive disorder, restlessness, suicidal ideation, suicidal tendencies, and completed suicide), and sleep disturbances (eg, abnormal dreams, insomnia, somnambulism) (Benard 2017; Glockler-Lauf 2019; Law 2018). In most cases, these reactions were reversible upon discontinuation (Perona 2016). Time to resolution may depend on the reaction (Benard 2017). Alternatively, some data suggest no association between montelukast and neuropsychiatric reactions (Ali 2015; Sansing-Foster 2021).

Mechanism: Non–dose-related; idiosyncratic (Chen 2014; Glockler-Lauf 2019).

Onset: Varied; within hours to years after therapy initiation (Glockler-Lauf 2019; Perona 2016).

Risk factors (information from very limited observational data):

• Increased asthma severity (Glockler-Lauf 2019)

• Increased number of concurrent asthma medications (eg, corticosteroids [inhaled or systemic], long-acting beta agonists (Benard 2017; Glockler-Lauf 2019)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Atopic dermatitis (children: ≥2%), dermatitis (children: ≥2%), eczema (children: ≥2%), skin infection (children: ≥2%), skin rash (2%), urticaria (children: ≥2%)

Gastrointestinal: Abdominal pain (children: ≥2%), diarrhea (children and adolescents: ≥2%), dyspepsia (2%), gastroenteritis (2%), nausea (children and adolescents: ≥2%), tooth infection (children: ≥2%), toothache (adolescents and adults: 2%)

Genitourinary: Pyuria (adolescents and adults: 1%)

Hepatic: Increased serum alanine aminotransferase (adolescents and adults: ≥1%), increased serum aspartate aminotransferase (adolescents and adults: 2%)

Infection: Influenza (children and adolescents: ≥2%), varicella zoster infection (children: ≥2%), viral infection (children and adolescents: ≥2%)

Nervous system: Dizziness (adolescents and adults: 2%), fatigue (adolescents and adults: ≤2%), headache (children and adolescents: ≥2%)

Neuromuscular & skeletal: Asthenia (adolescents and adults: ≤2%)

Ophthalmic: Conjunctivitis (children: ≥2%), myopia (children: ≥2%)

Otic: Otalgia (children: ≥2%), otitis (children and adolescents: ≥2%), otitis media (children and adolescents: ≥2%)

Respiratory: Acute bronchitis (children: ≥2%), cough (3%), epistaxis (adolescents and adults: ≥1%), laryngitis (children and adolescents: ≥2%), nasal congestion (adolescents and adults: 2%), pharyngitis (children: ≥2%), pneumonia (children: ≥2%), rhinitis (infective; children: ≥2%), rhinorrhea (children: ≥2%), sinus headache (adolescents and adults: ≥1%), sinusitis (≥1%), upper respiratory tract infection (≥1%)

Miscellaneous: Fever (2%), trauma (adolescents and adults: 1%)

Postmarketing:

Cardiovascular: Edema, eosinophilic granulomatosis with polyangiitis (Acoglu 2019; Calapai 2014; Lataifeh 2014; Nathani 2008), palpitations, vasculitis (Black 2009; Carlesimo 2011)

Dermatologic: Erythema multiforme, erythema nodosum, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis

Gastrointestinal: Pancreatitis, vomiting

Genitourinary: Urinary incontinence

Hematologic & oncologic: Bleeding tendency disorder, bruise, eosinophilia (systemic), thrombocytopenia

Hepatic: Hepatic eosinophilic infiltration, hepatitis (mixed pattern, hepatocellular, and cholestatic) (Russmann 2003)

Hypersensitivity: Anaphylaxis (Gerard 2009), angioedema (Sabbagh 2009)

Nervous system: Abnormal dreams (Benard 2017; Glockler-Lauf 2019; Law 2018), aggressive behavior (Benard 2017; Glockler-Lauf 2019; Law 2018), agitation (Benard 2017; Glockler-Lauf 2019; Law 2018), amnesia (Law 2018), anxiety (Benard 2017; Glockler-Lauf 2019; Law 2018), behavioral changes (Benard 2017), confusion (Law 2018), depression (Benard 2017; Glockler-Lauf 2019; Law 2018), disorientation (Law 2018), disturbance in attention (Law 2018), drowsiness (Benard 2017; Law 2018), hallucination (Law 2018), hostility, hyperactive behavior (Law 2018), hypoesthesia, insomnia (Law 2018), irritability (Benard 2017; Law 2018), lack of concentration (Law 2018), memory impairment (Law 2018), mood changes (Benard 2017; Glockler-Lauf 2019), nervousness (Law 2018), obsessive compulsive disorder, paresthesia, personality disorder (Law 2018), restlessness, seizure (Law 2018), somnambulism, stuttering, suicidal ideation (Glockler-Lauf 2019; Law 2018), suicidal tendencies (Glockler-Lauf 2019; Law 2018), tic disorder

Neuromuscular & skeletal: Arthralgia, muscle cramps, myalgia, tremor

Respiratory: Eosinophilic pneumonitis (Franco 1999)

Contraindications

Hypersensitivity to montelukast or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Eosinophilia and vasculitis: In rare cases, patients may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss); these clinical features may include eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy. A causal association between montelukast and these underlying conditions has not been established.

Disease related concerns:

• Acute asthma/bronchospasm: Montelukast is not FDA approved for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Some studies, however, support its use as adjunctive therapy (Cylly 2003; Ferreira 2001; Harmancik 2006). Appropriate rescue medications should be available. Montelukast treatment should continue during acute asthma exacerbations.

Dosage form specific issues:

• Chewable tablet: Contains phenylalanine.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Packet, Oral:

Singulair: 4 mg (30 ea)

Generic: 4 mg (1 ea, 30 ea)

Tablet, Oral:

Singulair: 10 mg

Generic: 10 mg

Tablet Chewable, Oral:

Singulair: 4 mg, 5 mg [contains aspartame]

Generic: 4 mg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Chewable (Montelukast Sodium Oral)

4 mg (per each): $5.03 - $5.66

5 mg (per each): $5.03 - $5.66

Chewable (Singulair Oral)

4 mg (per each): $10.50

5 mg (per each): $10.50

Pack (Montelukast Sodium Oral)

4 mg (per each): $5.66 - $8.22

Pack (Singulair Oral)

4 mg (per each): $10.50

Tablets (Montelukast Sodium Oral)

10 mg (per each): $0.06 - $5.66

Tablets (Singulair Oral)

10 mg (per each): $10.50

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Packet, Oral:

Singulair: 4 mg (30 ea)

Generic: 4 mg (30 ea)

Tablet, Oral:

Singulair: 10 mg

Generic: 10 mg

Tablet Chewable, Oral:

Singulair: 4 mg, 5 mg [contains aspartame]

Generic: 4 mg, 5 mg

Administration: Adult

Oral: In patients with asthma or who require chronic management of aspirin-exacerbated respiratory disease, administer dose in the evening regardless of the presence of other indications for montelukast (Ref); for all other indications, may individualize administration time. May administer without regard to food or meals.

Granules: May be administered directly in the mouth or mixed with a spoonful of cold or room temperature applesauce, carrots, rice, or ice cream; do not add to any other liquids or foods. Administer within 15 minutes of opening packet.

Administration: Pediatric

Oral: May administer without regard to food or meals. When treating asthma, administer dose in the evening. Patients with allergic rhinitis may individualize administration time (morning or evening). Patients with both asthma and allergic rhinitis should take their dose in the evening.

Granules: May be administered directly into the mouth, dissolved in 5 mL of cold or room temperature baby formula or breast milk, or mixed with a spoonful of cold or room temperature applesauce, carrots, rice, and ice cream; do not add to any other liquids or foods; administer within 15 minutes of opening the packet; liquids may be taken subsequent to administration.

Missed dose: The missed dose should be skipped and therapy resumed at next scheduled doses; two doses should not be administered at the same time to catch up.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Singulair: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020829s074,020830s0760,021409s052lbl.pdf#page=25

Use: Labeled Indications

Allergic rhinitis (perennial or seasonal): Relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients ≥2 years of age and perennial allergic rhinitis in adults and pediatric patients ≥6 months of age. Because the benefits may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have had an inadequate response or intolerance to alternative therapies.

Asthma (maintenance therapy): Prophylaxis and chronic treatment of asthma in adults and pediatric patients ≥12 months of age.

Bronchoconstriction, exercise-induced (prevention): Prevention of exercise-induced bronchoconstriction in adults and pediatric patients ≥6 years of age.

Note: American Academy of Otolaryngology-Head and Neck Surgery and American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma, and Immunology guidelines recommend against montelukast use as first-line therapy for allergic rhinitis (except in patients with concurrent asthma) (AAAAI/ACAAI [Dykewicz 2020]; AAO-HNSF [Seidman 2015]). The Global Initiative for Asthma recommends montelukast as add-on alternative therapy in patients with concomitant allergic rhinitis or those who are not maintained and/or who cannot take inhaled corticosteroids (GINA 2023).

Use: Off-Label: Adult

Aspirin-exacerbated respiratory disease (including aspirin challenge/desensitization); Hypersensitivity reactions, rapid chemotherapy/biologics desensitization (premedication); Infusion-related reactions, daratumumab-based regimens (premedication); Urticaria, chronic and delayed pressure

Medication Safety Issues
Sound-alike/look-alike issues:

Singulair may be confused with Oralair, SINEquan

Metabolism/Transport Effects

Substrate of CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Gemfibrozil: May increase the serum concentration of Montelukast. Risk C: Monitor therapy

Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination

Lumacaftor and Ivacaftor: May decrease the serum concentration of Montelukast. Risk C: Monitor therapy

Pregnancy Considerations

Outcome data following maternal use of montelukast during pregnancy are available (Bakhireva 2007; Cavero-Carbonell 2017; Hatakeyama 2022; Koren 2010; Nelsen 2012; Sarkar 2009; Van Zutphen 2015). Based on available data, an increased risk of teratogenic effects has not been observed with montelukast use during pregnancy (GINA 2023).

Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).

Pregnant patients adequately controlled on montelukast for asthma may continue therapy when conventional medications are not effective; initiating treatment during pregnancy is not recommended (Couillard 2021; ERS/TSANZ [Middleton 2020]).

Algorithms are available for the treatment of acute rhinitis and urticaria. Consider benefits and risks of treatment prior to use in pregnant patients (AAAAI/ACAAI [Dykewicz 2020]; EAACI [Zuberbier 2022])

Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (OTIS) (1-877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.

Breastfeeding Considerations

Montelukast is present in breast milk (Datta 2017).

Data related to the presence of montelukast in breast milk are available following chronic administration of oral montelukast 10 mg daily in 7 patients at 1.4 to 8.2 months' postpartum. All women were exclusively breastfeeding. Breast milk was sampled prior to and from 1 to 12 hours after the maternal dose. Using an average milk concentration of 5.3 ng/mL (average range: 2.87 to 9.12 ng/mL), authors of the study calculated the estimated exposure to the breastfeeding infant to be 0.798 mcg/kg/day (relative infant dose 0.68% based the weight-adjusted maternal dose). Adverse events were not reported in the mothers or breastfed infants (Datta 2017).

In general, breastfeeding is considered acceptable when the relative infant dose is <10% (Anderson 2016; Ito 2000).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Dietary Considerations

Some products may contain phenylalanine.

Monitoring Parameters

Neuropsychiatric events, including suicidal thinking/behavior.

Mechanism of Action

Selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Cysteinyl leukotrienes are also released from the nasal mucosa following allergen exposure leading to symptoms associated with allergic rhinitis (Jarvis, 2000).

Pharmacokinetics (Adult Data Unless Noted)

Duration: >24 hours

Absorption: Rapid

Distribution: Vd: 8 to 11 L

Protein binding, plasma: >99%

Metabolism: Extensively hepatic via CYP3A4, 2C8, and 2C9

Bioavailability: Tablet: 10 mg, Mean: 64%; Chewable tablet: 5 mg: 73% (63% when administered with a standard meal)

Half-life elimination: 2.7 to 5.5 hours; Mild-to-moderate hepatic impairment: 7.4 hours

Time to peak: Tablet: 10 mg: 3 to 4 hours (fasting); Chewable tablet: 4 mg (children 2 to 5 years): 2 hours (fasting); Chewable tablet 5 mg: 2 to 2.5 hours (fasting); Granules: 2.3 ± 1 hours (fasting) and 6.4 ± 2.9 hours (with high-fat meal)

Excretion: Feces (86%); urine (<0.2%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Following a single 10 mg dose, AUC increased 41% and half-life was prolonged to 7.4 hours in patients with mild-to-moderate hepatic impairment and cirrhosis. Patients with severe hepatic impairment or hepatitis have not been evaluated.

Pediatric: In children 6 to 23 months of age, the systemic exposure to montelukast is higher than in adults.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Airfast | Allair | Asthator | Astmast | Cinfalair | Denk air | Denk air junior | Ezeair | Glemont ct | Lukast | Lukra | M-kast | Monalti | Montair | Montikar | Montilag | Motrinex | Relukast | Singulair | Unicast | Xaira;
  • (AR) Argentina: Aireal | Amisped | Asmavitan | Denverkast | Inspirol | Lukair | Lukasma | Lukast | Montair | Monteluk | Montelukast richet | Montelukast teva | Montrate | Plenair | Rolast | Singulair;
  • (AT) Austria: Lanair | Montelukast accord | Montelukast actavis | Montelukast Chiesi | Montelukast Easypharm | Montelukast Genericon | Montelukast krka | Montelukast ratiopharm | Montelukast sandoz | Montelukast stada | Singulair;
  • (AU) Australia: Apo montelukast | Auro montelukast | Chemmart montelukast | Lukair | Montair | Montelair | Montelukast an | Montelukast gh | Montelukast lupin | Montelukast rbx | Montelukast sandoz | Pharmacor montelukast | Respikast | Singulair | T lukast | Terry white chemists montelukast;
  • (BD) Bangladesh: Aeron | Airmont | Airup | Airway | Amekast | Arokast | Arovent | Asmont | Brocast | Croma | Ezevent | Flomont | Freegest | Liam | Loctril | Lumenta | Luminus | Lumona | M lucas | M-kast | Maxair | Medikast | Mokast | Molukat | Molus | Monalast | Monark | Monas | Monkast | Monocast | Monovas | Monprox | Montair | Montek | Montekast | Montela | Montelon | Monteluk | Montenaaf | Montene | Montex | Montifast | Montilab | Montilet | Montinex | Montiva | Montril | Mts | Odmon | Provair | Pulmont | Reversair | Reversair ct | SB monec | Silmon | Tekast | Telukast | Trilock | Ventilast | Xyflo;
  • (BE) Belgium: Doc Montelukast | Montelsandoz | Montelukast Apotex | Montelukast eg | Montelukast eurogenerics | Montelukast Helm | Montelukast krka | Montelukast Mylan | Montelukast sandoz | Montelukast teva | Montemyl | Rhinosingulair | Singulair;
  • (BF) Burkina Faso: Monte | Montec | Telkast;
  • (BG) Bulgaria: Actamone | Alvokast | Ephyra | Monkasta | Monlucare | Montecon | Montelex | Montelukast gsk | Singulair | Spirokast;
  • (BR) Brazil: Aria | Monecast | Montelair | Montelucaste de sodio | Montelucaste de sodio ranbaxy | Montelucaste sodico | Monty | Multiler | Piemonte | Singulair | Singulair Baby | Uniair | Viatine | Zylcas;
  • (CH) Switzerland: Lukair | Montelukast actavis | Montelukast helvepharm | Montelukast mepha | Montelukast sandoz | Montelukast spirig hc | Singulair;
  • (CI) Côte d'Ivoire: Monte h | Romilast | Telkast;
  • (CL) Chile: Akan | Aliven | Asventol | Brondilat | Leukast | Lucaste | Lukanex | Monkast | Plenair | Singulair;
  • (CN) China: Bai san ping | Ping qi | Shu ning an | Singulair;
  • (CO) Colombia: Airbron | Aircys | Airomed | Aminofer | Amisped | Asmont | Blow | Bonvent | Cerrokast | Fastalive | Inmunokast | Kastamon | Kastmar | Leucotren | Leutrien | Lukast | Montelukast | Montelukast mk | Montemar | Montesher | Previasm | Profilax | Singulair | Suviar | Telux | Xalar;
  • (CZ) Czech Republic: Apo montelukast | Castispir | Miralust | Monkasta | Montecon | Montelar | Montelukast abbott | Montelukast accord | Montelukast actavis | Montelukast bluefish | Montelukast farmax | Montelukast gsk | Montelukast medreg | Montelukast Mylan | Montelukast orion | Montelukast stada | Montelukast teva | Singulair;
  • (DE) Germany: Lukastang | Monkasta | Montelair Hexal | Montelubronch | Montelukast | Montelukast 1 A Pharma | Montelukast Acis | Montelukast actavis | Montelukast AL | Montelukast ametas | Montelukast aristo | Montelukast Aurobindo | Montelukast axcount | Montelukast Biomo | Montelukast denk | Montelukast Dura | Montelukast fair med | Montelukast Glenmark | Montelukast Heumann | Montelukast Hormosan | Montelukast Juta | Montelukast Mylan | Montelukast puren | Montelukast ratiopharm | Montelukast stada | Montelukast zentiva | Montelunio | Singulair | Singulair mini;
  • (DO) Dominican Republic: Alergokast | Amisped | Asmabrit | Asmax | Everest | Iberlukas | Lukair | Lukanex | Lukastma | Lupriket | Monteluk | Montelukast | Montelukast lam | Montelukast mk | Montrate | Plenair | Plurair | Respiral | Singulair | Suviar | Telekast | Tuscasol | Uxigril | Xalar | Xyette;
  • (EC) Ecuador: Airlukast | Akan | Alergokast | Amisped | Andiar | Antibiox | Asmalair | Asmichem | Asventol | Blow | Capturan | Diuk | Everest | Everest m | Flimox | Glemont ct | Glemont IR | Inmunokast | Lukast | Lukastma | Luzka | Montecross | Montelukast | Montelukast la sante | Montelukast nifa | Montero | Piemonte | Profilax | Singulair | Suviar | Ventilar | Xalar;
  • (EE) Estonia: Lainmi | Mofenstra | Monkasta | Montelukast accord | Montelukast Genericon | Montelukast gsk | Montelukast orion | Montelukast Portfarma | Montelukast ratiopharm | Montelukast teva | Singulair | Singulair mini | Spirokast;
  • (EG) Egypt: Asmakast | Asmalair | Clear air | Delmonkast | Idulair | Inletair | Kast | Kokast | Montearab | Montekal | Montel | Montelair | Montelosab | Montelurama | Opikast | Pirontagonist | Relikast | Sedokast | Singukast | Singulair | Westair;
  • (ES) Spain: Monkasta | Montelukast | Montelukast accord | Montelukast actavis | Montelukast almus | Montelukast Alter | Montelukast amneal | Montelukast Apotex | Montelukast Aurobindo | Montelukast Aurovitas | Montelukast Cinfa | Montelukast Combix | Montelukast davur | Montelukast Kern | Montelukast Mabo | Montelukast Mylan | Montelukast Normon | Montelukast pensa | Montelukast pharmagenus | Montelukast Qualigen | Montelukast Ranbaxy | Montelukast ratiopharm | Montelukast sandoz | Montelukast stada | Montelukast Tarbis | Montelukast tecnigen | Montelukast teva | Montelukast ur | Montelukast vir | Montelukast zentiva | Pluralais | Singulair;
  • (ET) Ethiopia: Breathezy | Denk air | Monast | Montelukast | Montol | Montular | Singulair;
  • (FI) Finland: Airathon | Astecon | Imvlo | Montelukast | Montelukast accord | Montelukast actavis | Montelukast aspen | Montelukast krka | Montelukast Mylan | Montelukast orion | Montelukast ratiopharm | Montelukast sandoz | Montelukast teva | Singulair | Singulair-ar;
  • (FR) France: Montelukast accord | Montelukast actavis | Montelukast almus | Montelukast Alter | Montelukast arrow | Montelukast bgr | Montelukast Biogaran | Montelukast Cristers | Montelukast eg | Montelukast evolugen | Montelukast krka | Montelukast Mylan | Montelukast Phr | Montelukast Ranbaxy | Montelukast sandoz | Montelukast teva | Montelukast zentiva | Montelukast Zydus | Singulair;
  • (GB) United Kingdom: Denson | Montelukast | Montelukast teva | Singulair;
  • (GR) Greece: Apilone | Ascolin | Atentus | Brolyt | Miralust | Modrian | Modulair | Mokast | Molucar | Moncas | Montalis | Montast | Montelair | Montelukast sandoz | Montelukast teva | Montelukast/generics | Montelukast/krka | Montelukast/mylan | Montelukast/Teva | Pneumo Kast | Relukas | Singodem | Singulair | Singument s | Thordel | Velukast | Yekast | Zakomoxit;
  • (GT) Guatemala: Pulmokast;
  • (HK) Hong Kong: Akmont | Apo montelukast | Asmaact | Bronculair | Lukakline | Montelair | Montelucaste farmoz | Montelukast | Montelukast actavis | Montelukast sandoz | Montelukast teva | Montene | Montexin | Montulair | Odmon | Pms montelukast | Singulair;
  • (HR) Croatia: Melarth | Monkasta | Monlast | Montelukast PharmaS | Montelux | Singulair | Singulair mini | Surfair;
  • (HU) Hungary: Eonic | Miralust | Mokast | Monalux | Mondeo | Montelukast Mylan | Montelukast orion | Montelukast sandoz | Montelukast stada | Montelukast Synthon | Montelukast teva | Montep | Montexal | Revimont | Revimont Junior | Revimont mini | Singulair;
  • (ID) Indonesia: Bloktiene | Monarin | Rymont | Singulair;
  • (IE) Ireland: Montelair | Montelukast | Montelukast bluefish | Singulair;
  • (IL) Israel: Montelukast Trima | Singulair;
  • (IN) India: Admont | Almont | Astham | Asthamon | Breathezy | Crizlife | Emlucast | Lasma | Lastair | M-kast | Mont | Montair | Montegress | Montek | Montel Forte | Montelast | Montemac | Montemune | Monti | Montus | Monzem | Odimont | Romilast | Singulair | Solokast | Spiromont | Symkast | Telekast | Ventair;
  • (IQ) Iraq: Montix;
  • (IT) Italy: Airing | Brokast | Elunkast | Filkast | Fulmont | Leukast | Lukair | Lukanof | Lukasm | Lukavent | Mintalos | Monast | Monkasta | Monstonol | Montegen | Montelukast | Montelukast accord | Montelukast actavis | Montelukast Actavsi | Montelukast Angenerico | Montelukast Aurobindo | Montelukast Doc | Montelukast eg | Montelukast germed | Montelukast Mylan | Montelukast pensa | Montelukast pharmacare | Montelukast Ranbaxy | Montelukast sandoz | Montelukast tecnigen | Montelukast zentiva | Monterast | Moolpas | Perasm | Saslong | Singulair | Telelux;
  • (JO) Jordan: Airfast | Azma ban | Lukast | Moncas | Montal | Montas | Montolair | Motrinex | Sincast | Singulair | Unicast;
  • (JP) Japan: Kipres | Montelukast aa | Montelukast aspen | Montelukast ceo | Montelukast chemiphar | Montelukast cmx | Montelukast dsep | Montelukast ee | Montelukast jg | Montelukast kaken | Montelukast km | Montelukast kn | Montelukast ko | Montelukast meiji | Montelukast nichiiko | Montelukast nippon zoki | Montelukast nipro | Montelukast nissin | Montelukast nitto | Montelukast ohara | Montelukast pfizer | Montelukast sandoz | Montelukast sanwa | Montelukast sawai | Montelukast sn | Montelukast sodium nippon zoki | Montelukast takata | Montelukast takeda teva | Montelukast towa | Montelukast tsuruhara | Montelukast yd | Montelukast zeria | Singulair;
  • (KE) Kenya: Aeron | Aireez | Almont | Asthator | Breathezy | Kipel | Luxat | M-kast | Maclair | Mastic | Monaka | Monas | Monluke | Montair | Montallerg ct | Montana | Monte h | Montene | Montiget | Montikast | Montized | Moral | Myteka | Odimont | Romilast | Singulair | Solo | Telkast | Ucon;
  • (KR) Korea, Republic of: Allermont | Ari montelukast fine granule | Ascare | Asluka | Asthcare | Asthluka | Asthmon | Asthmon chew | Asthmonte | Clisto | Clistso | Curost | Daewoong montelukast | Delair | Dongkwang montelukast | Eluka | Glolair | Glolare | Glorair | Huglare | Ingulair | Kasmon | Kuhnil montelukast | Lairst | Luca rare | Luica | Luika | Lukas | Lukast | Lukatrin | Lukema | Lukio | Mediluka | Medimonte | Mediruka | Moneca | Monka | Monkalus | Monkast | Monkasula | Monolair | Monoluka | Monstella | Montair | Monte | Monte k | Montecall | Monteforce | Montegen | Monteka | Montekan | Montekas | Montel | Montela | Montelair | Montelien | Montelienchew | Montelock | Montelol | Montelon | Montelos | Montelu | Montelu v | Montelucan | Monteludi | Monteludin | Monteluk | Montelukan | Montelukast | Montelus | Montem | Monten | Montena | Montenew | Monteone | Montepect | Montepos | Monteq | Montequal | Montera | Monterin | Monteriu | Montero | Monteron | Monteros | Montesco | Montesin | Montesium | Montest | Montestal | Montestar | Montezal | Montrair | Monukan | Newmontekat | Onceair | Pneumast | Rukair | Samsung montelukast | Sandoz montelukast | Singkalus | Singkast | Singula | Singulair | Singular | Singuldown | Singuless | Singulien | Singulmax | Singulmon | Singulod | Singulstar | Singuluka | Sinkast | Terakas | Unimonst;
  • (KW) Kuwait: Airfast | Cinfalair | Clear air | Montas | Motrinex | Singulair | Unicast;
  • (LB) Lebanon: Airfast | Leukotris | Lukast | Montelukast sandoz | Motrinex | Romilast | Sincast | Singulair | Unicast | Zespira;
  • (LT) Lithuania: Astmir | Eonic | Mofenstra | Monkasta | Montelukast | Montelukast Actiopharma | Montelukast alvogen | Montelukast orion | Montelukast Portfarma | Montelukast ratiopharm | Montelukast teva | Singulair | Spirokast;
  • (LU) Luxembourg: Montelukast Mylan | Montelukast sandoz | Montelukast teva | Rhinosingulair | Singulair;
  • (LV) Latvia: Monkasta | Montelukast accord | Montelukast alvogen | Montelukast ratiopharm | Otemon | Singulair | Singulair mini;
  • (MA) Morocco: Airfastec | Flowair | Romilast | Singulair;
  • (MX) Mexico: Abbatin | Araumed | Cubraxis | Cubraxis m | Debrexst | Drimon | Everest | Frenderil | Glubtina | Inhalst | Katsoraam | Maselle | Maselle m | Miletic | Monalti | Monk | Monk p | Montelukast | Montelukast antibioticos | Montipedia | Montipedia cr | Montipedia sg | Ontronon | Riskal m | Sakulur | Sansibast | Senloir | Senovital | Sinbrux | Singulair | Speradac | Staixi | Staytal | Staytal m | Talfrod | Tempxis | Tempxis m | Urilast | Valtrover | Valtrover m;
  • (MY) Malaysia: Accord montelukast | Airlukast | Altra | Apo montelukast | Aspira | Astalair | Asthator | Avalair | Bloktiene | Glemont | Hovid Montelukast | M-kast | Monast | Monkasta | Montelair | Montelukast | Montelukast sandoz | Montemac | Montexin | Montiget | Montular | Oxair | Pediair | Singulair;
  • (NG) Nigeria: Monast | Montelukast | Montiget | Singulair | Telkast;
  • (NL) Netherlands: Montelukast abdi | Montelukast accord | Montelukast actavis | Montelukast amarox | Montelukast Aurobindo | Montelukast CF | Montelukast Mylan | Montelukast sandoz | Montelukast teva | Singulair;
  • (NO) Norway: Montelukast | Montelukast 1 A Pharma | Montelukast aspen | Montelukast teva | Singulair;
  • (NZ) New Zealand: Montelukast | Montelukast Mylan | Montelukast viatris | Singulair;
  • (OM) Oman: Montas;
  • (PE) Peru: Airlukast | Ambril | Asmexx | Blow | Brolukat | Glemont ct | Glemont IR | Inmunokast | Kastmar | Leutrien | Lipasmat | Monte lukano | Montelukast | Montemar | Piemonte | Plenair | Prevenil | Singulair | Ventilair;
  • (PH) Philippines: Aerokids | Aeromax | Airmaxx | Airokast | Asmaact | Asmaflo | Aurohex | Averkaz | Brecare | Bronast | Dialukast | Duramont | Glemont | Kastair | Kastel | Kastorion | Leukast | Leukorex | Lucazt | Lukas | Mastic | Mocast | Monalti | Montecad | Montekast | Montekaz | Montel | Montela | Montelair | Montelox | Montelukast | Montelukast sandoz | Montemax | Montezyd | Montiget | Moscalair | Primeair | Singulair | Sydenkast | Tekast | Teluk | Terrakast | Ventek;
  • (PK) Pakistan: Adkast | Aerokast | Aerotel | Aireez | Airmont | Airon | Airy | Amisped | Anamont | Ardis | Asfree | Askat | Asmakast | Asmont | Asteck | Astel | Asthiven | Astikast | Beasy | Benkast | Bresco | Bronast | Bronchokast | Bronkeez | Bronokast | Bronsecur | C kast | Cingol | Clinair | Conkast | Daycast | Dilair | Dune | Exma | Fasmont | Fasmount | Fastair | Floaid | Freehale | G mont | Healkast | Helakast | Ikast | Indokast | Inspra | Irmax | Jamont | Jukast | Kasbe | Kasbex | Kast | Kilair | Lakas | Leukastin | Leukotrack | Leukurb | Leykast | Linaksat | Livair | Lokast | Lokastdale | Lucast | Lukastin | Lukomon | Lukrx | Lulast | Lungair | Mac | Mcast | Mckast | Mecost | Mekast | Mekast pediatric | Mekofin | Melukast | Metost | Mingair | Mks | Mntk | Molus | Mon | Monaka | Monbro | Moncher | Moncit | Monest | Monpal | Monsuka | Montair | Montana | Montaza | Montec | Montef | Montekan | Montekarl | Montel | Montelair | Montelo | Montemax | Montemore | Montenovex | Monter | Monterel | Montero | Monteser | Montewan | Montewns | Montheim | Monti | Monticast | Monticel | Montiget | Montigrat | Montika | Montil | Montilak | Montimed | Montiroz | Montisel | Montisim | Montit | Montiwel | Moor | Mucosoft | Mykast | Mylakast | Myteka | Myti | Nenkast | Neomont | Neskay | Nomika | Novokast | Noweez | Openair | Pelbim | Polergen | Prevasma | Provair | Pulmease | Pulmikast | Purgo | Radikast | Rayair | Regulair | Remikair | Renmont | Repsil | Respicare | Respirel | Rocktel | Rolekast | Saydokast | Season | Selectikast | Sidkast | Simkast | Singulair | Slokast | Sokadium | Sokast | Solara | Solo | Sontel | Sydokast | Synkast | Tair | Telekast | Telkair | Telukast | Temonet | Umcast | Unilocast | Vankast | Velukast | Ventek | Ventomax | Victor | Vividone | Whizix | Winkast | Wintel;
  • (PL) Poland: Asmenol | Astmirex | Astmodil | Drimon | Eonic | Hardic | Milukante | Montelak | Montelukast arrow | Montelukast Aurobindo | Montelukast Aurovitas | Montelukast bluefish | Montelukast Lek am | Montelukast medreg | Montelukast sandoz | Montelukast stada | Montelukastum 123 ratio (drimon) | Montespir | Montessan | Montest | Orilukast | Promonta | Romilast | Singulair | Spirokast | Symlukast | Vizendo;
  • (PR) Puerto Rico: Singulair;
  • (PT) Portugal: Lukair | Montelucast | Montelucaste Actavis | Montelucaste Alter | Montelucaste aurobindo | Montelucaste Azevedos | Montelucaste baldacci | Montelucaste bluepharma | Montelucaste chesmon | Montelucaste ciclum | Montelucaste farmoz | Montelucaste generis | Montelucaste krka | Montelucaste labesfal | Montelucaste Mylan | Montelucaste pharmakern | Montelucaste ratiopharm | Montelucaste sandoz | Montelucaste tecnigen | Montelucaste Tecnilor | Montelucaste teva | Montelucaste Tolife | Singulair;
  • (PY) Paraguay: Amisped | Asventol | Brondilat | Inmunobron | Leukaler | Lukanex | Montelair | Piemonte | Singulair | Telukast | Vymolets;
  • (QA) Qatar: Airfast | Apo-Montelukast | Asthator | Cinfalair | Cinfalair Paediatrics | Lukast | Moncas | Montal | Montas | Montiget | Monty | Motrinex | Onceair | Sin-Mont | Singulair | Unicast;
  • (RO) Romania: Asthator | Astmasan | Monkasta | Montelukast cipla | Montelukast medreg | Montelukast teva | Vizendo;
  • (RU) Russian Federation: Almont | Ektalust | Glemont | Monax | Monkasta | Monler | Monte r | Montelar | Montelast | Montelukast | Montelukast sanofi | Montelukast zentiva | Simplaer | Singlon | Singulair | Singulex;
  • (SA) Saudi Arabia: Airfast | Allair | Antikast | Apo montelukast | Bremax | Broncast | Bronchofast | Leukair | Leukast | Lukra | Moncas | Montas | Montek | Montel | Motrinex | Pms montelukast | Singulair | Unicast | Yocair | Zecast;
  • (SE) Sweden: Lukasm | Montegen | Montelukast 2care4 | Montelukast accord | Montelukast actavis | Montelukast aspen | Montelukast bluefish | Montelukast ebb | Montelukast krka | Montelukast Mylan | Montelukast orion | Montelukast Ranbaxy | Montelukast sandoz | Montelukast stada | Montelukast teva | Singulair | Singulair-ar;
  • (SG) Singapore: Actamone | Apo montelukast | Lukakline | Monast | Montelair | Montelukast mevon | Montelukast sandoz | Pms montelukast | Regulair | Singulair;
  • (SI) Slovenia: Actamone | Mofenstra | Monkasta | Montelukast teva | Singulair;
  • (SK) Slovakia: Actamone | Astmasan | Belokast | Miralust | Monkasta | Montelukast | Montelukast accord | Montelukast medreg | Montelukast Mylan | Montelukast orion | Montelukast stada | Montelukast teva | Montexal | Singulair | Spiromon;
  • (TH) Thailand: Astair | Montek | Montelukast | Montulair | Singkast | Singulair;
  • (TN) Tunisia: Asmulair | Astair | Moncas | Montelukast Mylan | Onceair | Singulair;
  • (TR) Turkey: Airfix | Airlast | Alecast | Aliento | Clast | Luxat | Medlukast | Monax | N Fess | Notta | Onceair | Respair | Selezen | Sin mont | Singulair | Ventilar | Zespira;
  • (TW) Taiwan: Anxokast | Monkast | Monte h | Monteka | Montelukast | Montexin | Montezyd | Singulair | Sinkast | Sinlukast;
  • (UA) Ukraine: Asmont | Astator | Culento | Glemont | Lucast | Milukante | Montegen | Montel | Montelukast | Montular | Montular kids | Moral | Onceair | Singulair | Synglon;
  • (UG) Uganda: Asthator | Breathezy | Breathezy cw | Glemont ct 4 | Glemont ct 5 | Kipel | Martinez | Montair | Monte h | Montelair | Montemac | Myteka | Odimont | Telkast | Unicast;
  • (UY) Uruguay: Inmunobron | Monkast | Montelair | Piemonte | Plenair | Plenaler m10 | Plenaler m4 | Plenaler m5 | Singulair;
  • (VE) Venezuela, Bolivarian Republic of: Aircof | Airon | Caste | Inuvic | Lukastab | Montecort | Montekvin | Montelukast | Montrax | Monukast | Roweluk | Singulair | Suviar;
  • (VN) Viet Nam: Asthmatin | Atilair chew | Atmurcat | Bronlucas | Derdiyok | Givet | Leukas | Meyerlukast | Miowan | Montestad | Murtakat | Phagofi | Simguline | Smart air | Usalukast;
  • (ZA) South Africa: Almont | Antaluko | Belair | Kulair | Lumont | Minair | Monte Air | Monteflo | Montelukast cipla | Montelukast lhc | Montelukast unicorn | Singulair | Sintair | Sintrine | Topraz;
  • (ZM) Zambia: Asthator | Breathezy | Montair | Romilast | Sintrine | Telkast;
  • (ZW) Zimbabwe: Asthator | Breathezy | Breathezy cw | Lukast | Monast | Montera | Romilast | Sandoz montelukast | Singulair | Sintrine | Telkast
  1. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  2. Bakhireva LN, Jones KL, Schatz M, et al. Organization of Teratology Information Specialists Collaborative Research Group. Safety of Leukotriene Receptor Antagonists in Pregnancy. J Allergy Clin Immunol. 2007;119(3):618-625. [PubMed 16708374]
  3. Barr H, Dempsey J, Waller A, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32(11):2495-2518. doi:10.1038/s41375-018-0120-2 [PubMed 29679038]
  4. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. [PubMed 24766875]
  5. Boyce JA. Antileukotriene agents in the management of asthma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 12, 2021.
  6. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259-1266. doi:10.1016/j.jaci.2009.09.009 [PubMed 19910036]
  7. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102(2):155-160. doi:10.1016/S1081-1206(10)60247-5 [PubMed 19230468]
  8. Camargo CA Jr, Smithline HA, Malice MP, et al. A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma. Am J Respir Crit Care Med. 2003;167(4):528-533. [PubMed 12456380]
  9. Castells M, Solensky R. Rapid drug desensitization for immediate hypersensitivity reactions. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 10, 2021.
  10. Cavero-Carbonell C, Vinkel-Hansen A, Rabanque-Hernández MJ, Martos C, Garne E. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res. 2017;109(6):452-459. doi:10.1002/bdra.23621 [PubMed 28398707]
  11. Couillard S, Connolly C, Borg C, Pavord I. Asthma in pregnancy: an update. Obstet Med. 2021;14(3):135-144. doi:10.1177/1753495X20965072 [PubMed 34646341]
  12. Cylly A, Kara A, Ozdemir T, et al, “Effects of Oral Montelukast on Airway Function in Acute Asthma,” Respir Med, 2003, 97(5):533-6. [PubMed 12735671]
  13. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9-14. doi:10.1164/ajrccm.165.1.2010080 [PubMed 11779723]
  14. Datta P, Rewers-Felkins K, Baker T, Hale TW. Transfer of montelukast into human milk during lactation. Breastfeed Med. 2017;12:54-57. [PubMed 28002678]
  15. deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 25, 2023.
  16. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619-625. [PubMed 15356567]
  17. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007 [PubMed 32707227]
  18. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  19. Ferreira MB, Santos AS, Pregal AL, et al, “Leukotriene Receptor Antagonists (Montelukast) in the Treatment of Asthma Crisis: Preliminary Results of a Double-Blind Placebo Controlled Randomized Study,” Allerg Immunol (Paris), 2001, 33(8):315-8.
  20. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020. Accessed May 6, 2020.
  21. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.
  22. Harmanci K, Bakirtas A, Turktas I, et al, “Oral Montelukast Treatment of Preschool-Aged Children With Acute Asthma,” Ann Allergy Asthma Immunol, 2006, 96(5):731-5. [PubMed 16729788]
  23. Hatakeyama S, Goto M, Yamamoto A, et al. The safety of pranlukast and montelukast during the first trimester of pregnancy: aprospective, two-centered cohort study in Japan. Congenit Anom (Kyoto). 2022;62(4):161-168. doi:10.1111/cga.12471 [PubMed 35538631]
  24. Hofmeister CC, Lonial S. How to integrate elotuzumab and daratumumab into therapy for multiple myeloma. J Clin Oncol. 2016;34(36):4421-4430. doi:10.1200/JCO.2016.69.5908 [PubMed 27998219]
  25. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000; 343(2):118-126. [PubMed 10891521]
  26. Jarvis B and Markham A, "Montelukast: A Review of Its Therapeutic Potential in Persistent Asthma," Drugs, 2000, 59(4):891-928. [PubMed 10804041]
  27. Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 10, 2021.
  28. Koren G, Sarkar M, Einarson A. Safety of using montelukast during pregnancy. Can Fam Physician. 2010;56(9):881-882. [PubMed 20841587]
  29. Kulthanan K, Ungprasert P, Tuchinda P, Chularojanamontri L, Charoenpipatsin N, Maurer M. Delayed pressure urticaria: a systematic review of treatment options. J Allergy Clin Immunol Pract. 2020;8(6):2035-2049.e5. doi:10.1016/j.jaip.2020.03.004 [PubMed 32179196]
  30. Laidlaw TM, Israel E. Aspirin-exacerbated respiratory disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 10, 2021.
  31. Lougheed MD, Lemière C, Dell SD, et al, “Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,” Can Respir J, 2010, 17(1):15-24. [PubMed 20186367]
  32. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132-141. doi:10.1016/S0140-6736(19)32956-3 [PubMed 31836199]
  33. Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971-977. doi:10.1111/ddg.12194 [PubMed 24034140]
  34. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019 [PubMed 31699837]
  35. Moore DC, Arnall JR, Thompson DL, et al. Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab. Clin Lymphoma Myeloma Leuk. 2020;20(10):e777-e781. doi:10.1016/j.clml.2020.05.024 [PubMed 32660902]
  36. Nelsen LM, Shields KE, Cunningham ML, et al, "Congenital Malformations Among Infants Born to Women Receiving Montelukast, Inhaled Corticosteroids, and Other Asthma Medications," J Allergy Clin Immunol, 2012, 129(1):251-4. [PubMed 22000568]
  37. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34(9):1401-1407. [PubMed 15347373]
  38. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;155(6):1279-1282. doi:10.1111/j.1365-2133.2006.07533.x [PubMed 17107402]
  39. O'Byrne PM. Exercise-induced bronchoconstriction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 10, 2021.
  40. Pacor ML, Di Lorenzo G, Corrocher R, et al, "Efficacy of Leukotriene Receptor Antagonist in Chronic Urticaria. A Double-Blind, Placebo-Controlled Comparison of Treatment With Montelukast and Cetirizine in Patients With Chronic Urticaria With Intolerance to Food Additive and/or Acetylsalicylic Acid," Clin Exp Allergy, 2001, 31(10):1607-14. [PubMed 11678862]
  41. Parsons JP, Hallstrand TS, Mastronarde JG, et al; American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016-1027. doi:10.1164/rccm.201303-0437ST [PubMed 23634861]
  42. Philip G, Hustad CM, Malice MP, et al, “Analysis of Behavior-Related Adverse Experiences in Clinical Trials of Montelukast,” J Allergy Clin Immunol, 2009a, 124(4):699-706. [PubMed 19815116]
  43. Philip G, Hustad C, Noonan G, et al, “Reports of Suicidality In Clinical Trials Of Montelukast,” J Allergy Clin Immunol, 2009b, 124(4):691-6. [PubMed 19815114]
  44. Refer to manufacturer's labeling.
  45. Sánchez-Borges M, Asero R, Ansotegui IJ, et al; WAO Scientific and Clinical Issues Council. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5(11):125-147. [PubMed 23282382]
  46. Sarkar M, Koren G, Kalra S, et al, “Montelukast Use During Pregnancy: A Multicentre, Prospective, Comparative Study of Infant Outcomes,” Eur J Clin Pharmacol 2009, 65(12);1259-64. [PubMed 19707749]
  47. Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1)(suppl):S1-S43. [PubMed 25644617]
  48. Simon RA. Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 12, 2021b.
  49. Simon RA, Cutlip D. Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 10, 2021a.
  50. Singulair (montelukast) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.
  51. Singulair (montelukast) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; May 2021.
  52. Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2021;147(3):827-844. doi:10.1016/j.jaci.2020.10.043 [PubMed 33307116]
  53. Van Zutphen AR, Bell EM, Browne ML, Lin S, Lin AE, Druschel CM; National Birth Defects Prevention Study. Maternal asthma medication use during pregnancy and risk of congenital heart defects. Birth Defects Res A Clin Mol Teratol. 2015;103(11):951-961. doi:10.1002/bdra.23437 [PubMed 26408052]
  54. Wan KS. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2009;20(4):194-197. [PubMed 19085267]
  55. White AA, Stevenson DD, Woessner KM, Simon RA. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc. 2013;34(2):138-142. doi:10.2500/aap.2013.34.3644 [PubMed 23484888]
  56. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13(4):293-859. doi:10.1002/alr.23090 [PubMed 36878860]
  57. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090 [PubMed 34536239]
Topic 9539 Version 556.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟